FMP
DiaMedica Therapeutics Inc.
DMAC
NASDAQ
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
6.41 USD
1.54 (24.02%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Dietrich John Pauls MBA
sector
Healthcare
industry
Biotechnology
website
https://www.diamedica.comexchange
NASDAQ
Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutic...
CIK
0001401040
ISIN
CA25253X2077
CUSIP
25253X207
Address
Two Carlson Parkway
Phone
763 612 6755
Country
US
Employee
18
IPO Date
Aug 3, 2012
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
DMAC Financial Summary
CIK
0001401040
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
25253X207
ISIN
CA25253X2077
Country
US
Price
6.41
Beta
1.46
Volume Avg.
82.84k
Market Cap
274.1M
Shares
-
52-Week
2.14-6.41
DCF
0.13
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-11.45
P/B
-
Website
https://www.diamedica.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest DMAC News
It looks like there's no news available.
